In spite of the same quality of life score at the fi rst session of chemotherapy (74.5 out of 100), after fi nishing the chemotherapy cycle, patients in TAC arm had the lower score of QOL (64 in TAC vs. 68 in FAC) and higher range of toxicity and their medical costs were higher as well (the average costs in TAC was 391,176,968.2 Rials vs. 2,427,775.2 in FAC). ICER was negative that showed the dominant result for FAC comparing with TAC. CONCLUSIONS: It seems that because of the short horizon of the study, TAC regimen had the worse impact on the patient's quality of life during the chemotherapy cycle because of more side effects than FAC. It is believed that there is need for other studies with longer time horizons and specifi c attention to the effects of these treatments on survival and quality of life. OBJECTIVES: Breast cancer is known to be one of the leading causes of death among the female population. Preventive measures may provide an economic and outcome advantage by reducing treatment costs and increasing survival. The objective of this study was to evaluate the cost-effectiveness of a breast cancer vaccine versus current standard treatments. METHODS: TreeAge software was used to calculate the costeffectiveness. a decision tree was constructed for different probabilities of success and failure for the vaccine versus standard treatment. Costs and outcomes (life-years saved) ranges were obtained from published clinical trials. The vaccine effectiveness was projected from animal studies, with human clinical trials expected within a year. The range of effectiveness of the vaccine was considered between 30% and 90% with a baseline at 80%. The costs included for standard treatments ranged from $20,000 to $45,000 and the cost of the vaccine was assumed at $450 for three doses; therefore, the cost for vaccine ranged from $300 to $2000 depending on the number of doses. The incremental cost-effectiveness ratios were calculated from the range of costs and outcomes. Sensitivity analyses were performed to determine the robustness of the fi ndings. RESULTS: Vaccination was found to be a potentially cost-effectiveness option with an ICER of 2384.146 relative to standard treatment. The incremental effectiveness was 8.2 life-years saved. The highest cost-effectiveness of the vaccine was at 90% success and a cost of not more than $1000 per individual. Sensitivity analyses indicated that the vaccine remained cost-effective over the range of model parameters. CONCLUSIONS: The breast cancer vaccine was projected to be the most costeffective treatment option in this analysis. It is expected that better screening for breast cancer vaccine patient candidates will be available in the future.
PCN90 COMPARATIVE RETROSPECTIVE NON-RANDOMIZED PHARMACOECONOMIC TRIAL OF EFFICIENCY AND SAFETY OF USE OF PACLITAXELS (PACLITAXEL-LENS OR TAXOL) IN A MONOMODE FOR 2ND LINE OF TREATMENT OF METASTATIC BREAST CANCER PATIENTS
Pavlysh A 1 , Kolbin A 2 , Livshits R 2 , Koroleva O 2 , Manikhas A 1 , Tkachenko E 1 , Atrashevskaya N 1 , Demicheva N 1 1 Saint Petersburg City Clinical Oncology Dispensary, Saint Petersburg, Russi; 2 Saint Petersburg State University, Saint Petersburg, Russia OBJECTIVES: For the fi rst time in a modern Russian economic conditions, it has been made pharmacoeconomics trial (PE) uses Russian generic of paclitaxel (Paclitaxel-Lens [PL]) in comparison with original drug (Taxol (T)) at chemotherapy (ChT) in a monomode for 2nd line of metastatic breast cancer (MBC) in real clinical practice. METHODS: It has been provided retrospective comparative nonrandomized clinical trial which have been included 70 patients for 35 patients of each group (PL or T) after analysis of 148 case records. RESULTS: At the analysis of effectively treatment MBC in group of the patients who have received T, the partial remission (PR, 28.5% against 10%) statistically signifi cantly has been more often reached. At the analysis of safety, it has been shown that in group of the patients who have received PL, statistically signifi cantly has been more often fi xed hepatotoxicity (23.3% against 3.8%) and an anemia (19.2% against 3.5%). In group of the patients who have received T, statistically signifi cantly has been more often fi xed arthralgia/ myalgia (29.8% against 0%). Total direct costs (DC) in group of patients with T also there were above, than in group of PL, namely $10,727 and $9765 accordingly. Calculation of effi ciency of expenses has shown that treatment of MBC by T more expensive and more effective, than treatment by PL. CONCLUSIONS: Thus, as a result of research, it has been established that: 1) Applying of T was more (from 7% to 11%) expensive, than PL, but gave the PR is much more often; 2) The alternative scenario and the sensitivity analysis shown to choose conditions when application of compared drugs will be economically more expedient; and 3) Thus, it is necessary to take into consideration, what application of PL was more often accompanied by hepatotoxicity and anemia, like arthralgia/ myalgia after using of T. of paclitaxel + 6 mg/mL/min of carboplatin versus 500 mg/m 2 of pemetrexed and 75 mg/m 2 of cisplatin was assessed based on a systematic review performed for both therapies according to evidence-based medicine principles. A cost-effectiveness analysis was performed with a lifetime (5 years) horizon and the National Health Fund perspective. a three state (progressionfree, progression, death) Markov model was developed. Costs of 1st and 2nd line therapy, administration and monitoring, adverse events treatment, and palliative care were included. Sensitivity analyses testing the infl uence of length of time horizon, probability of progression, utilities, discounting rates, cisplatin dose, and the length and costs of 2nd line therapy were performed. RESULTS: Bev + Pac + Car results in 0.21 life-years gained per patient when compared to Pem + Cis in the treatment of patients with adenocarcinoma non-squamous NSCLC. The additional cost per patient was 18,840 pln (1 EURO = 4.1PLN) over patient's lifetime when Bev + Pac + Car was used instead of Pem + Cis regimen. The incremental cost-effectiveness ratio (ICER) was at an acceptable 91,216 pln. The sensitivity analyses demonstrated that the duration of 2nd line treatment (assumption of 2nd line treatment continuation for more than six cycles) considerably infl uenced the ICER (1,198 pln) . Other sensitivity analyses confi rmed the base-case results, proving conclusions' robustness. CONCLUSIONS: Based on this modeling analysis, 1st line Bev + Pac + Car therapy is a clinically superior and cost-effective treatment for patients with adenocarcinoma non-squamous NSCLC when compared to chemotherapies such as Pem + Cis.
PCN91 BEVACIZUMAB + PACLITAXEL + CARBOPLATIN (BEV + PAC + CAR) VS. PEMETREXED + CISPLATIN (PEM + CIS) IN ADENOCARCINOMA NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COST-EFFECTIVENESS ANALYSIS FROM A POLISH PUBLIC PAYER'S PERSPECTIVE

PCN92 PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC EVALUATION OF OXALIPLATIN IN PALLIATIVE CHEMOTHERAPY OF METASTATIC COLORECTAL CANCER (MCCR)
Kolbin A 1 , Orlova R 2 , Pavlysh A 3 , Llivshits M 1 1 Saint Petersburg State University, Saint Petersburg, Russia; 2 Saint Petersburg Medical Academy of Postgraduate Education, Saint Petersburg, Russia; 3 Saint Petersburg City Clinical Oncology Dispensary, Saint Petersburg, Russia The problem of original drugs substitution on generics presents in the Russian clinical practice due to rational expenditures allocation. Pharmaceutical bioequivalence of generic should be confi rmed by therapeutic one. Only after such kind of confi rmation, the mentioned substitution could be made in different segments of doctors' practice especially in anticancer chemotherapy. OBJECTIVES: To evaluate the clinical-economic interchangeability of the original oxaliplatin Eloxatine (EL) and local generic Exorum (EX) in the chemotherapy of mCCR. METHODS: The retrospective clinicaleconomic analysis of FOLFOX scheme for chemotherapy of mCCR with EL and EX in the real practice has been performed. Fifty case histories (23 with using of EL, 27-EX, was used nomogram of Altman's) were studied. The calculation of direct cost and cost-effectiveness ratio (CER) based on "partial regress + stabilization" parameter no less than 80% has been performed. RESULTS: For achievement of equal effi cacy EL had less number of chemotherapy cycles and total dosage compared with EX (5,0 and 7,3; 670 mg and 900 mg, respectively). Adverse effects were more frequent in EX versus EL (59 and 38, respectively) and caused additional costs and prolonged hospitalization (9 days/patient compared to EL group). The utilitarian EX program cost per patient was less compared to EL by 7,7%. In the same time, CER calculated with total costs due to side effects treatment was practically equal (difference is 1,6% only). Cost prognosis for equal effi cacy results with EL using is less by 28,6% versus EX. The alternative scenario has confi rmed the cinical-economic added value of EL. CONCLUSIONS: The change of original EL for generic EX in FOLFOX scheme for mCCR has no economic advantages. EL substitution leads to increased number of chemotherapy cycles, higher dose of oxaliplatin, higher rate of adverse effects, and higher costs. 
